Recent Articles from TheStreet

Microsoft Names Qualcomm Executive Hou Yang As New Greater China Chief

Microsoft to Require Proof of Vaccination for U.S. Office Entry

Microsoft will require employees to show proof they are vaccinated against COVID-19 before they can enter any company facility in the U.S.

Jim Cramer: How Robinhood Turned E*Trade Into a Dinosaur

Robinhood Stock Jumps, Exceeds IPO Price of $38

Robinhood stock jumped double digits on Tuesday, exceeding its IPO price of $38.

Nvidia Lead

Nvidia Stock Flat as U.K. Reportedly Might Block Arm Deal

An assessment of Nvidia's acquisition of Arm contains implications for U.K. national security, a media report says.

Alibaba Lead

Alibaba Stock Needs to Reclaim This Level of Support After Earnings

Alibaba stock desperately needs to reclaim a key level of support, but so far it hasn't been able to. Let's look at the charts.

Marvell Technology Lead

Marvell, Building Cloud Business, Will Buy Innovium for $1.1 Billion

Marvell Technology, looking to build its cloud business, plans to acquire networking-chip provider Innovium for $1.1 billion of stock.

25 4 people gas car driving kids sh

TurboTax: Don't Overlook the Additional Child Tax Credit

If you can't claim the full Child Tax Credit, you may be eligible to claim the refundable Additional Child Tax Credit.

US-China Tech War: Beijing Calls On Chinese Firms To 'seize Overseas Opportunities' In Race For Self-reliance

Hollysys Stock Upgraded by J.P. Morgan After Higher Buyout Bid

Hollysys said it received a bid of $23 cash a share from a group including its founder. That tops a $17.10-a-share proposal from another group.

Failing Hibbett Sports Just Tossed Serious Shade on Under Armour's Lack of Cool

Five Top Stock Gainers for Tuesday: Under Armour, ZoomInfo, Translate Bio

Under Armour, ZoomInfo, Translate Bio, Outlook Therapeutics and Arcturus Therapeutics are five top gainers for Tuesday.

Camping World Lead

Camping World Stock Slips After Mixed Earnings Report

Camping World's revenue jumped 28% to $2.06 billion in the second quarter but trailed analysts’ consensus estimate.

Outlook Therapeutics Lead

Outlook Therapeutics Stock Soars on Positive Results for Eye Treatment

Outlook Therapeutics plans to submit an application to the Food and Drug Administration.